AstraZeneca PLC
$166.54-2.36Market Cap
$246.2B
Global Rank
#60
All-Time High
$302.7B
2026-07-03
Total Growth
+0%
since 2026
Market Cap Context
- Larger than 84% of the 367 companies we track (globally).
- Equivalent to 6.2% of United Kingdom's GDP (2025 data).
- Just above: #59 Shell plc ($250.0B)
- Just below: #61 SAP SE ($242.0B)
- Best year: 1995 (+47%). Worst year: 2004 (-23%).
AstraZeneca PLC Financial Breakdown (FY 2025)
Source: Yahoo Finance — AZN annual filings (2025) →$58.7B revenue · $13.3B operating income · $10.2B net income
- ●Operating margin: 22.7% on $58.7B in revenue.
- ●R&D is 24.2% of revenue ($14.2B).
- ●Net income margin: 17.4% — $10.2B in profit.
- ●Free cash flow: $8.7B (14.8% of revenue).
Cost / Operating Expenses
Total operating expenses $45.4B
Total
$45.6B
Capital Expenditures
$5.9B
This fiscal year (near-total AI infrastructure buildout)
Free Cash Flow
$8.7B
Trailing twelve months
Figures rounded from the annual SEC filing. Unaudited. For informational purposes only, not investment advice.
Fundamentals (TTM)
Data: Financial Modeling PrepP/E
—
EPS
—
Net margin
—
ROE
—
Dividend yield
—
Debt / Equity
—
About AstraZeneca PLC
AstraZeneca plc (AZ) is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
AstraZeneca PLC Market Cap History (2026–2026)
AstraZeneca PLC vs Sector Peers by Market Cap
Compare AstraZeneca PLC
Ranking History
| Year | Market Cap | Rank | YoY Change |
|---|---|---|---|
| 2026 | $246.2B | #60(↓17) | -12.8% |
| 2025 | $282.2B | #43(↑7) | +43.3% |
| 2024 | $196.9B | #50(↓2) | -0.6% |
| 2023 | $198.1B | #48(↓9) | +1.4% |
| 2022 | $195.3B | #39(↑18) | +19.2% |
| 2021 | $163.9B | #57(↑2) | +19.7% |
| 2020 | $136.9B | #59(↓13) | +3.1% |
| 2019 | $132.8B | #46(↑2) | +35.7% |
| 2018 | $97.9B | #48(↑6) | +13.9% |
| 2017 | $85.9B | #54(↑5) | +33.2% |
| 2016 | $64.5B | #59(↓12) | -15.8% |
| 2015 | $76.6B | #47(↓2) | +0.5% |
| 2014 | $76.2B | #45(↑4) | +23.6% |
| 2013 | $61.7B | #49(↑2) | +33.2% |
| 2012 | $46.3B | #51(↓5) | +8.5% |
| 2011 | $42.7B | #46(↑4) | +6.0% |
| 2010 | $40.3B | #50(↓4) | +3.5% |
| 2009 | $38.9B | #46(↓9) | +20.3% |
| 2008 | $32.3B | #37(↑28) | +0.2% |
| 2007 | $32.3B | #65(↓20) | -17.5% |
| 2006 | $39.1B | #45(↓3) | +13.3% |
| 2005 | $34.5B | #42(↑10) | +36.9% |
| 2004 | $25.2B | #52(↓19) | -23.4% |
| 2003 | $32.9B | #33(↑3) | +40.8% |
| 2002 | $23.4B | #36(↑4) | -23.2% |
| 2001 | $30.5B | #40(↑7) | -7.9% |
| 2000 | $33.1B | #47(↓3) | +28.7% |
| 1999 | $25.7B | #44(↓10) | -5.7% |
| 1998 | $27.2B | #34(↑1) | +27.0% |
| 1997 | $21.4B | #35(↓2) | +31.7% |
| 1996 | $16.3B | #33(↓1) | +47.0% |
| 1995 | $11.1B | #32(↓2) | +47.3% |
| 1994 | $7.5B | #30 |
Other Healthcare Companies
FAQ
What is AstraZeneca PLC's market cap?
AstraZeneca PLC (AZN) has a market capitalization of $246.2B, making it the #60 largest company in the world by market cap.
What was AstraZeneca PLC's highest market cap?
AstraZeneca PLC's all-time high market cap was $302.7B, reached in 2026-07-03. Its highest rank was #43 in 2025.
What sector is AstraZeneca PLC in?
AstraZeneca PLC is in the Healthcare sector, specifically the Drug Manufacturers - General industry. It is based in United Kingdom.
How has AstraZeneca PLC's market cap changed over time?
AstraZeneca PLC has been tracked since 2026. Its market cap has grown by 0% from $246.2B in 2026 to $246.2B today.